Table 3.

HLA-DPB1 supertype frequency in relation to leukaemia karyotype

DPB1 supertypea	Control %	TEL-AML1				HeH				OTHER
		%	OR	95% CIb	2 sided p	%	OR	95% CI	2 sided p	%	OR	95% CI	2 sided p
GKD	11.1	4.7	0.42	0.22–0.81	0.005	5.2	0.44	0.30–0.65	0.00001	8.1	0.72	0.53–0.97	0.03
GKG	58.0	57.4	0.97	0.72–1.31	0.91	61.2	1.14	0.94–1.38	0.19	58.9	1.04	0.87–1.23	0.71
LKD	13.2	13.2	1.01	0.65–1.56	0.99	10.8	0.80	0.60–1.07	0.15	11.4	0.85	0.65–1.11	0.24
GED	0.5	2.6	6.00	2.11–17.05	0.01	1.5	3.25	1.31–8.04	0.03	0.9	2.01	0.77–5.23	0.28
GEG	6.8	11.6	1.83	1.14–2.94	0.03	10.3	1.59	1.15- 2.19	0.008	10.8	1.66	1.24–2.23	0.001
LED	5.2	6.3	1.28	0.70–2.34	0.58	7.7	1.54	1.07–2.21	0.03	7.7	1.55	1.10–2.17	0.01
N c	864			95				300				381

^aDPB1 supertype designations as shown in Table 2

^bOR, 95% CI: Odds ratios and 95% confidence intervals

^c N  number of subjects